Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
05/23 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23 MERCK : Announces Third-Quarter 2017 Dividend
05/23 MERCK & CO., INC. (NYSE : MRK) ISENTRESS Receives Positive Opinion From CHMP
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/23 MERCK : FDA Grants Priority Review to Merck’s Supplemental Biologics Licen..
05/22 MERCK : Announces Presentation of Phase 2 Results for MK-7264, an Investigationa..
05/22 MERCK : Contractor Hits 5 Million Safe Hours
05/20 MERCK : CHMP Adopts Positive Opinion For Isentress 600 Mg In EU
More news
Sector news : Pharmaceuticals - NEC
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
05/23DJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/23DJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/23 PFIZER VS. MERCK : 4 Reasons One Is The Superior Choice
05/23 FDA OKs Merck's Keytruda for certain solid tumors
05/23 Merck & Co's (MRK) Annual Shareholders Meeting Brokers Conference (Transcript..
05/23 Merck declares $0.47 dividend
05/23 FDA tags Merck's Keytruda supplemental BLA for Priority Review for gastric/es..
Advertisement
Financials ($)
Sales 2017 39 930 M
EBIT 2017 13 655 M
Net income 2017 7 128 M
Debt 2017 942 M
Yield 2017 2,91%
P/E ratio 2017 24,85
P/E ratio 2018 18,83
EV / Sales 2017 4,45x
EV / Sales 2018 4,32x
Capitalization 176 555 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,3 $
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.9.65%175 160
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
SANOFI14.93%124 306
More Results